Truvestments Capital’s Biogen BIIB Stock Holding History

Truvestments Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19	Closed	-$3.48K	–	1161
2026 Q1	$3.48K	Sell	19 -14	-42%	-$2.58K	﹤0.01%	941
2025 Q4	$5.81K	Hold	33	–	–	﹤0.01%	781
2025 Q3	$4.66K	Sell	33 -35	-51%	-$4.73K	﹤0.01%	836
2025 Q2	$8.57K	Hold	68	–	–	﹤0.01%	663
2025 Q1	$9.3K	Sell	68 -8	-11%	-$1.14K	﹤0.01%	669
2024 Q4	$11.6K	Buy	76 +40	+111%	+$6.75K	﹤0.01%	581
2024 Q3	$6.98K	Buy	+36	New	+$7.53K	﹤0.01%	639
2024 Q1	–	Sell	-55	Closed	-$14.2K	–	742
2023 Q4	$14.2K	Hold	55	–	–	0.01%	486
2023 Q3	$14.1K	Hold	55	–	–	0.01%	421
2023 Q2	$15.7K	Buy	+55	New	+$16.4K	0.01%	408
2023 Q1	–	Sell	-12	Closed	-$3.32K	–	699
2022 Q4	$3.32K	Hold	12	–	–	﹤0.01%	621
2022 Q3	$3K	Hold	12	–	–	﹤0.01%	505
2022 Q2	$2K	Buy	+12	New	+$2.45K	﹤0.01%	551
2019 Q3	–	Sell	-200	Closed	-$47K	–	696
2019 Q2	$47K	Hold	200	–	–	0.03%	289
2019 Q1	$47K	Buy	+200	New	+$63K	0.04%	286
2018 Q3	$71K	Buy	+200	New	+$68.9K	0.03%	312

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Truvestments Capital's BIIB Position: Q2 2026 in Review

Truvestments Capital sold out of Biogen (BIIB) in Q2 2026, closing a stake of 19 shares — an estimated $3.48K sold.

Truvestments Capital first reported a position in BIIB in Q3 2018 and held it in 16 quarters. The position peaked at $71K in Q3 2018. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Truvestments Capital reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Truvestments Capital sold 19 Biogen shares in Q2 2026, an estimated $3.48K.
Truvestments Capital first reported a position in Biogen in Q3 2018 and held it in 16 quarters.
Truvestments Capital's Biogen position peaked at $71K in Q3 2018.
1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.